Fast response within 24 hours
The mechanistic rationale for adjunctive use is strong
Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy
More recently, the SELECT trial (2023) extended these findings to adults with obesity but without diabetes, demonstrating a 20% cardiovascular event reduction and significant improvements in LDL cholesterol, non-HDL cholesterol, and triglyceride levels
Non-GMO NOTE: If you have a medical condition, are pregnant, lactating, trying to conceive, under the age of 18, or taking medications, consult your healthcare professional before using this product.
Enzymatic degradation (pancreatin) Stock solutions of the oligomers were prepared at a concentration of 250 M in DMSO